Skip to content

Study · Randomized controlled trial · n = 18 · 2019

4 results

The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial.

Jepsen DB, Ryg J, Hansen S, Jørgensen NR, Gram J, Masud T

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA15 Jul 2019Cited by 43 (Europe PMC)

PMID31309239 (opens in a new tab)PMCIDPMC6717187 (opens in a new tab)DOI10.1007/s00198-019-05029-z (opens in a new tab)PepBankPUB-31309239
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, lumbar spine BMD increased by 6.65% with teriparatide alone over 12 months.

    In plain wordsIn women with osteoporosis, spine bone density increased by 6.65% with teriparatide alone over 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD change with teriparatide alone
    Study

    n = 18

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 12 monthsAs given in this study (human).

    Measurements

    BMD change
    6.65%
    teriparatide alone

    Source sentences

    Summary
    The teriparatide + WBV group increased by (mean ± SD) 8.90% ± 5.47 and the teriparatide group by 6.65% ± 5.51.
    3 context sentences
    Summary · context
    At 12 months, both groups increased significantly in BMD at the lumbar spine.
    Summary · context
    The PaVOS study is a randomized controlled trial where postmenopausal osteoporotic women starting teriparatide 20 μg/day were randomized to WBV + teriparatide or teriparatide alone.
    Summary · context
    Thirty-five women were randomized (17 in teriparatide + WBV group and 18 in teriparatide group).

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, adding whole-body vibration to teriparatide increased lumbar spine BMD more than teriparatide alone.

    In plain wordsIn women with osteoporosis, vibration exercise plus teriparatide increased spine bone density more than teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n = 35

    Comparator
    Teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    BMD change
    8.9%
    teriparatide plus WBV
    BMD change
    6.65%
    teriparatide alone
    Adjusted treatment effect
    2.95%
    adding WBV

    Source sentences

    Summary
    The adjusted treatment effect of adding WBV to teriparatide was statistically significant at 2.95% [95% CI = 0.14-5.77; P = 0.040].
    3 context sentences
    Summary · context
    The teriparatide + WBV group increased by (mean ± SD) 8.90% ± 5.47 and the teriparatide group by 6.65% ± 5.51.
    Summary · context
    At 12 months, both groups increased significantly in BMD at the lumbar spine.
    Summary · context
    The PaVOS study is a randomized controlled trial where postmenopausal osteoporotic women starting teriparatide 20 μg/day were randomized to WBV + teriparatide or teriparatide alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialMechanism

    In women with osteoporosis, bone turnover markers increased in both groups without significant differences between vibration plus teriparatide and teriparatide alone.

    In plain wordsIn women with osteoporosis, bone turnover markers increased similarly with vibration plus teriparatide and teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone turnover markers
    Study

    n = 35

    Comparator
    Teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Markers of bone turnover increased significantly in both groups at three and six months with no significant difference between groups.
    1 context sentence
    Summary · context
    The PaVOS study is a randomized controlled trial where postmenopausal osteoporotic women starting teriparatide 20 μg/day were randomized to WBV + teriparatide or teriparatide alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialOther

    In women with osteoporosis, adding vibration exercise to teriparatide showed no other treatment effects on hip BMD, bone microarchitecture, or sclerostin.

    In plain wordsIn women with osteoporosis, vibration plus teriparatide showed no additional effects on hip bone density, bone structure, or sclerostin compared with teriparatide alone.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeOther bone outcomes
    Study

    n = 35

    Comparator
    Teriparatide alone
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    No other treatment effects were observed in hip BMD, bone microarchitecture parameters, or sclerostin levels in either group.
    1 context sentence
    Summary · context
    The PaVOS study is a randomized controlled trial where postmenopausal osteoporotic women starting teriparatide 20 μg/day were randomized to WBV + teriparatide or teriparatide alone.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT02563353

PTH and Vibration in OSteoporosis Study

Odense University Hospitaln = 35Nov 2015 to Nov 2019

Osteoporosis

Trial pageClinicalTrials.govUpdated 18 Sept 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.